Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.45 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.45 |
| ▸ | CPB1 | P15086 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 5/20 | 0.42 |
| ▸ | PPARG | P37231 | 4/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.41 |
| ▸ | ITGAL | P20701 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3009900 | 1.00 | ITGB3 (0.47) | ITGB3ITGA2BACEITGA4ITGB7 | |
| SCHEMBL3009904 | 1.00 | ITGB3 (0.47) | ITGB3ITGA2BACEITGA4ITGB7 | |
| SCHEMBL24997209 | 0.88 | ITGB3 (0.47) | ITGB3ITGA2BACEITGA4ITGB7 | |
| SCHEMBL689786 | 0.87 | CPB2 (0.45) | ITGA4ITGB7CPB2CPB1ITGB2 | |
| SCHEMBL689785 | 0.87 | CPB2 (0.45) | ITGA4ITGB7CPB2CPB1ITGB2 | |
| SCHEMBL6329225 | 0.86 | CPB2 (0.64) | ITGB3ITGA2BACEITGA4ITGB7 | |
| SCHEMBL6321412 | 0.86 | CPB2 (0.49) | ITGB3ITGA2BCPB2CPB1ITGB2 | |
| SCHEMBL3008885 | 0.85 | ITGB3 (0.45) | ITGB3ITGA2BACEITGA4ITGB7 | |
| SCHEMBL13650201 | 0.85 | ITGB3 (0.45) | ITGB3ITGA2BACEITGA4ITGB7 | |
| SCHEMBL3008889 | 0.85 | ITGB3 (0.45) | ITGB3ITGA2BACEITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732466-B2 | Substituted thiophene carboxamides, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-08 | — | — | US | disclosed |
| US-20060293300-A1 | New substituted thiophene carboxamides, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-28 | — | — | US | disclosed |
| US-7115609-B2 | Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases | ELI LILLY AND COMPANY (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040254374-A1 | Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases | ELI LILLY AND COMPANY | 2004-12-16 | — | — | US | disclosed |
| EP-1456198-A1 | ALANYL-PIPERIDINE HETEROCYCLIC DERIVATIVES USEFUL AGAINST CARDIOVASCULAR DISEASES | ELI LILLY AND COMPANY (US) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003050109-A1 | ALANYL-PIPERIDINE HETEROCYCLIC DERIVATIVES USEFUL AGAINST CARDIOVASCULAR DISEASES | ELI LILLY AND COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254374-A1 | Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases | XPNPEP1, XDH, SERPINC1 | ITGB3 1683/4885ITGA2B 983/4885ACE 798/4885 |
| US-20060293300-A1 | New substituted thiophene carboxamides, process for their preparation and their use as medicaments | OTC, TPMT, ABCG2 | ITGB3 3790/4885ITGA2B 3614/4885ACE 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.